Kazia Therapeutics Limited

ASX:KZA.AX

0.08 (AUD) • At close November 13, 2023
Bedrijfsnaam Kazia Therapeutics Limited
Symbool KZA.AX
Munteenheid AUD
Prijs 0.08
Beurswaarde 18,907,919
Dividendpercentage 0%
52-weken bereik 0.051 - 0.24
Industrie Biotechnology
Sector Healthcare
CEO Dr. John E. Friend II, M.D.
Website https://www.kaziatherapeutics.com

An error occurred while fetching data.

Over Kazia Therapeutics Limited

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company

Vergelijkbare Aandelen

Prescient Therapeutics Limited logo

Prescient Therapeutics Limited

PTX.AX

0.041 AUD

Cann Group Limited logo

Cann Group Limited

CAN.AX

0.038 AUD

Proteomics International Laboratories Limited logo

Proteomics International Laboratories Limited

PIQ.AX

0.6 AUD

Vita Life Sciences Limited logo

Vita Life Sciences Limited

VLS.AX

2.15 AUD

SDI Limited logo

SDI Limited

SDI.AX

0.98 AUD

SomnoMed Limited logo

SomnoMed Limited

SOM.AX

0.44 AUD

Financiële Gegevens

Cijfers zijn in miljoenen (AUD)

Cijfers zijn in miljoenen (AUD)